当前位置: »论坛 › 科研专区 › 文献互助› CLN-978, a novel half-life extended CD19/CD3/HSA-spe ...

[BMJ] CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

求助已关闭

Weirstrass 发表于 4 天前 | 显示全部楼层 |阅读模式

悬赏30积分

期刊：Journal for ImmunoTherapy of Cancer

文献作者：Kristan Meetze; Naveen K Mehta; Bochong Li; Hannah M Findlay; Timothy B London; Agapitos Patakas; Jennifer S Michaelson; Patrick A Baeuerle

出版日期：2023-8-

DOI号：10.1136/jitc-2023-007398

下载链接：https://syndication.highwire.org ... 36/jitc-2023-007398

文献链接：https://doi.org/10.1136/jitc-2023-007398

当前文献来源于 BMJ。

备注信息：

使用道具捐赠获取积分应助有误反馈

全部回复0 显示全部楼层

发表回复

Weirstrass Lv.3

高级会员

发布
回复
积分
370

同分类求助

30 Injury prediction in sports using artificial intelligence (IPredict-AI) (PhD Academy Award)

[BMJ] CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[BMJ] CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression 一键复制

发表回复

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[BMJ] CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression